
Agenus (AGEN) Stock Forecast & Price Target
Agenus (AGEN) Analyst Ratings
Bulls say
Agenus Inc has a robust pipeline of therapies aimed at harnessing the immune system to combat cancer and infections, supported by in-house capabilities such as cGMP manufacturing. The company's compassionate use program for its antibody candidates, botensilimab and balstilimab, is anticipated to generate additional revenue and yield real-world clinical evidence for their applications, particularly in breast cancer treatments. Encouraging early regulatory sentiment for these therapies in various indications further enhances the company's growth potential and overall market outlook.
Bears say
Agenus Inc faces several significant risks that contribute to a negative outlook on its stock. Key concerns include the potential for emerging safety signals in its clinical and preclinical programs, which could undermine investor confidence and impact trials. Furthermore, the company may encounter challenges related to efficacy, competition in the market, regulatory hurdles, financing needs, and intellectual property protection, all of which add to uncertainty regarding its product pipeline and overall financial stability.
This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.
Agenus (AGEN) Analyst Forecast & Price Prediction
Start investing in Agenus (AGEN)
Order type
Buy in
Order amount
Est. shares
0 shares